An overview of the potentialities and recent advances in nanotechnology-based systems for glucocorticoids delivery

 

An Overview of the Potentialities and Recent Advances in Nanotechnology-Based Systems for Glucocorticoid Delivery

Glucocorticoids (GCs) have long been considered powerful anti-inflammatory and immunosuppressive agents, used to treat a wide range of conditions—from asthma and rheumatoid arthritis to autoimmune disorders. However, their systemic administration often leads to severe side effects such as osteoporosis, hypertension, and metabolic dysfunction. This challenge has prompted researchers to explore smarter, more targeted delivery methods—enter nanotechnology.

Why Nanotechnology for Glucocorticoids?

Nanotechnology offers a platform to enhance drug delivery efficiency, minimize off-target effects, and improve therapeutic outcomes. By encapsulating glucocorticoids into nanoscale carriers, it’s possible to control drug release, protect the drug from degradation, and deliver it directly to diseased tissues.

Types of Nanocarriers Used

Several types of nanocarriers have been developed for glucocorticoid delivery:

  • Lipid-Based Nanoparticles (Liposomes, Solid Lipid Nanoparticles): These biocompatible carriers improve drug solubility and reduce toxicity. Liposomal formulations can selectively accumulate in inflamed tissues through the enhanced permeability and retention (EPR) effect.

  • Polymeric Nanoparticles: Biodegradable polymers like PLGA and PEG can provide sustained release, reducing dosing frequency.

  • Nanomicelles and Dendrimers: These systems enhance stability and enable precise targeting through surface modification.

  • Inorganic Nanoparticles: Gold and silica nanoparticles are emerging as promising platforms due to their tunable surface chemistry and imaging compatibility.

Recent Advances and Applications

Recent research highlights several innovations:

  • Targeted Delivery: Functionalizing nanoparticles with antibodies or peptides allows selective binding to inflamed or cancerous tissues, enhancing therapeutic precision.

  • Stimuli-Responsive Systems: Smart nanocarriers can release glucocorticoids in response to specific triggers such as pH, temperature, or enzymatic activity.

  • Combination Therapies: Co-delivery systems that pair glucocorticoids with other anti-inflammatory or immunomodulatory drugs are being explored to improve efficacy.

Clinical Translation and Future Prospects

While most studies are still in preclinical stages, some nanoformulations are moving closer to clinical testing. The ultimate goal is to develop safe, efficient, and patient-friendly delivery systems that can reduce systemic side effects while maintaining the powerful therapeutic benefits of glucocorticoids.

Conclusion

Nanotechnology represents a transformative approach in glucocorticoid therapy. By enabling targeted, controlled, and sustained delivery, nanocarriers may soon redefine how these essential drugs are administered—ushering in a new era of precision medicine in inflammation management.

8th Edition of Scientists  Research Awards | 27-28 October 2025 | Paris, France

Get Connected

Visit Our Website : scientistsresearch.com Nominate Now : scientistsresearch.com/award-nomination/? ecategory=Awards&rcategory=Awardee Contact us : support@scientistsresearch.com Social Media Facebook : www.facebook.com/profile.php?id=61573563227788 Pinterest : www.pinterest.com/mailtoresearchers/ Instagram : www.instagram.com/scientistsresearch/ Twitter : x.com/scientists2805 Tumblr : www.tumblr.com/dashboard Scientists Research Awards. #scientificreason #researchimpact #futurescience #scienceinnovation #researchleadership #stemeducation #youngscientists #GlobalResearch #scientificachievement #sciencecommunity #innovationleadership #academicresearch

Comments

Popular posts from this blog